NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)
Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock following a conference call with a medical physicist hosted by Mizuho on October 17. Highlights from the discussion included numerous key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC. Among other highlights, the consultant noted that the most important achievement of MRIdian is its ability to improve treatment effectiveness due to greater visualization of patients’ internal anatomy compared to traditional alternatives such as X-Ray technology. Specifically, MRI-LINAC delivers substantial improvements in soft-tissue tracking and protection of sensitive surrounding organs.…







